# US 2023/0234934 A1 · Bioactive phenolate ionic complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0234934 A1
- Document ID: US20230234934A1
- Status: Published application
- Kind: A1
- Application number: 17/996,694
- Filed: 2021-04-21
- Published: 2023-07-27
- Earliest claimed: 2020-04-22
- Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem; Hadasit Medical Research Services and Development Ltd.
- Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.; Hadasit Medical Research Services & Development Limited
- Inventors: Abraham Jacob DOMB; Noam STEINMAN; Yakir ROTTENBERG
- Web page: https://patentgrep.com/patent/US20230234934A1

## CPC

- C07C 39/23: polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
- C07D 311/80: Dibenzopyrans; Hydrogenated dibenzopyrans
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- C07C 37/00: Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C 37/66: by conversion of hydroxy groups to O-metal groups
- C07C 39/235: Metal derivatives of a hydroxy group bound to a six-membered aromatic ring
- C07C 49/84: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 69/88: with esterified carboxyl groups
- C07C 215/40: with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
- C07C 235/60: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07D 223/16: Benzazepines; Hydrogenated benzazepines
- C07D 233/16: Radicals substituted by nitrogen atoms
- C07C 2601/16: the ring being unsaturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides an isolated material, or a phenolate form of at least one phenol- containing active material, wherein the isolated material comprises one or more phenolate species and a counter ion (a cation) in the form of a metal salt, a phosphonium or an ammonium.

## Claims

### Claim at position 1

1-85. (canceled)

### Claim 86

An isolated material comprising at least one phenol-containing active material and a metal salt, a phosphonium or an ammonium salt counter-ion, wherein the active material is not phenol (C6H6O), methylphenol, bromophenol, dibromophenol, tribromophenol, pentachlorophenol, bisphenol A, tetrabromobisphenol A, resorcinol, hydroquinone, hydroquinone or naphthol.

### Claim 87 (depends on 86)

The material according to claim 86, being in the form of an ammonium salt or a phosphonium salt.

### Claim 88 (depends on 86)

The material according to claim 86, comprising a divalent metal and two phenolate active materials.

### Claim 89 (depends on 86)

The material according to claim 86, comprising two or more phenolic-active materials, each active material having one or more phenolate groups, each of the phenolate groups being associated with a different cation selected from a metal cation, a phosphonium cation and an ammonium cation.

### Claim 90 (depends on 88)

The material according to claim 88, wherein the two phenolate active materials are the same or different.

### Claim 91 (depends on 86)

The material according to claim 86, comprising a trivalent metal and three same or different phenolate active materials.

### Claim 92 (depends on 88)

The material according to claim 88, wherein one or more of the phenolate active materials is an agricultural material.

### Claim 93 (depends on 86)

The material according to claim 86, comprising one or more phenolate active material and one or more non-active phenolate material.

### Claim 94 (depends on 86)

The material according to claim 86, wherein the phenolate active material is selected from cannabinoids, fenoldopam, tyrosine, xylenol, thymol, propofol, apomorphine, morphine and derivatives thereof, mitoxantrone, dexorubicine, hexachlorophene, acetaminophen, p-coumaric acid, 3,4-dihydroxybenzoic acid, 4-hydroxybenzoic acid, butylparaben, vanillic acid, guaiacol, caffeic acid, tolterodine, raloxifea, scopoletin, decursinol, dopamine, L-DOPA, curcumin, tianine and polyphenols.

### Claim 95 (depends on 94)

The material according to claim 94, wherein the active drug entity is a cannabinoid material.

### Claim 96 (depends on 95)

The material according to claim 95, wherein the cannabinoid is THC or CBD and chemical derivatives thereof.

### Claim 97

A material comprising at least one cannabinoid in a form of a phenolate and a cation selected from metal cations, phosphonium and ammonium.

### Claim 98

A calcium CBD salt comprising one CDB and optionally another non-cannabinoid or two CBDs.

### Claim 99

A material being a cholate salt of at least one phenol active material.

### Claim 100 (depends on 99)

The material according to claim 99, wherein the active drug entity is a cannabinoid material.

### Claim 101 (depends on 86)

A formulation selected from a pharmaceutical, cosmetic, veterinary or agricultural formulation, the formulation comprising an isolated material according to claim 86.

### Claim 102 (depends on 86)

A material according to claim 86, being in the form of a multimolecular material comprising two or more phenol-containing active materials, each being ionically associated with a cation; wherein the cation is a multivalent metal cation or a poly-ammonium.

### Claim 103 (depends on 86)

A particle comprising a material according to claim 86.

### Claim 104

A composition or a formulation comprising a material, wherein the material comprising an ammonium cation or a poly-ammonium, and at least one active material comprising at least one phenolate moiety ionically bonded to the ammonium or the poly-ammonium cation, wherein the composition or the formulation is for use in treating a disease or disorder which is treatable by administering to a subject a therapeutically effective amount of the composition or the formulation.
